Gynaecological (uterine/ovarian)
Gynaecological cancer is one of the six research themes in the Cancer Research UK Scotland Centre & is also integral to Glasgow Experimental Cancer Medicines Centre.
Staff
Publications
2025
Cartwright, D., Kidd, A. C., Ansel, S., Ascierto, M. L., Spiliopoulou, P. (2025) Oncogenic signalling pathways in cancer immunotherapy: leader or follower in this delicate dance? International Journal of Molecular Sciences, 26, (doi: 10.3390/ijms26094393)
Woraharn, W., McCulloch, A., Bigley, C., Hatthakarnkul, P., Pennel, K., Alexander, P., Van Wyk, H., Roseweir, A., Hay, J., Maka, N., Park, J., Jamieson, N. B., Edwards, J., Roxburgh, C. S.D. (2025) Investigation of three alternative histopathological scoring methods at the invasive tumour front in colorectal cancer. Journal of Pathology: Clinical Research, 11, (doi: 10.1002/2056-4538.70031)
Dolan, R. D., Pennel, K., Thompson, J., McKenzie, M., Alexander, P., Richards, C., Black, D., Abbass, T., Maka, N., McGovern, J., Roseweir, A., McSorley, S. T., Horgan, P. G., Roxburgh, C., McMillan, D. C., Edwards, J. (2025) The relationship between tumour necrosis, systemic inflammation, body composition and survival in patients with colon cancer. BJC Reports, 3, (doi: 10.1038/s44276-024-00119-w)
2024
Pennel, K., Kurniawan, A., Al-Badran, S. S. F., Schubert Santana, L., Quinn, J., Nixon, C., Hatthakarnkul, P., Maka, N., Roxburgh, C., McMillan, D., Edwards, J. (2024) IL6 and IL6R as prognostic biomarkers in colorectal cancer. Biomolecules, 14, (doi: 10.3390/biom14121629)
Krebs, M. G., Forster, M., Majem, M., Peguero, J., Iams, W., Clay, T., Roxburgh, P., Doger, B., Bajaj, P., Barba, A., Perera, S., Mueller, C., Triebel, F. (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5, (doi: 10.1016/j.jtocrr.2024.100725)
Galbraith, N. J., Quinn, J. A., Al-Badran, S. S., Pennel, K. A.F., Hillson, L. V.S., Hatthakarnkul, P., McKenzie, M., Maka, N., Loi, L., Frixou, M., Steele, C. W., Roxburgh, C. S., Horgan, P. G., McMillan, D. C., Edwards, J. (2024) TAK1 expression is associated with increased PD-L1 and decreased cancer-specific survival in microsatellite-stable colorectal cancer. Translational Oncology, 48, (doi: 10.1016/j.tranon.2024.102064)
Churchhouse, A. M.D., Billard, C. V., Suzuki, T., Pohl, S. O.G., Donnelly, K., Nixon, C., Arends, M. J., Din, S., Kirkwood, K., Marques Junior, J., Von Kriegsheim, A., Coffelt, S. B., Myant, K. B. (2024) Loss of DOCK2 potentiates Inflammatory Bowel Disease-associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression. Oncogene, 43, pp. 3094-3107. (doi: 10.1038/s41388-024-03135-9)
Knight, K., Bigley, C., Pennel, K., Hay, J., Maka, N., McMillan, D., Park, J., Roxburgh, C., Edwards, J. (2024) The Glasgow Microenvironment Score: an exemplar of contemporary biomarker evolution in colorectal cancer. Journal of Pathology: Clinical Research, 10, (doi: 10.1002/2056-4538.12385)
McKenzie, M., Lian, G.-Y., Pennel, K. A.F., Quinn, J. A., Jamieson, N. B., Edwards, J. (2024) NFκB signalling in colorectal cancer: examining the central dogma of IKKα and IKKβ signalling. Heliyon, 10, (doi: 10.1016/j.heliyon.2024.e32904)
Kumar, S., Basto, A. P., Ribeiro, F., Almeida, S. C.P., Campos, P., Peres, C., Pulvirenti, N., Al-Khalidi, S., Kilbey, A., Tosello, J., Piaggio, E., Russo, M., Gama-Carvalho, M., Coffelt, S. B., Roberts, E. W., Geginat, J., Florindo, H. F., Graca, L. (2024) Specialized Tfh cell subsets driving type-1 and type-21 humoral responses in lymphoid tissue. Cell Discovery, 10, (doi: 10.1038/s41421-024-00681-0)
Peters, A.L., Hall, P.S., Jordan, L.B., Soh, F.Y., Hannington, L., Makaranka, S., Urquhart, G., Vallet, M., Cartwright, D., Marashi, H., Elsberger, B. (2024) Enhancing clinical decision support with genomic tools in breast cancer: a Scottish perspective. Breast, 75, (doi: 10.1016/j.breast.2024.103728)
Wiesheu, R. et al. (2024) IL-27 maintains cytotoxic Ly6C+ T cells that arise from immature precursors. EMBO Journal, (doi: 10.1038/s44318-024-00133-1)
Sumaria, N., Fiala, G. J., Inácio, D., Curado-Avelar, M., Cachucho, A., Pinheiro, R., Wiesheu, R., Kimura, S., Courtois, L., Blankenhaus, B., Darrigues, J., Suske, T., Almeida, A. R. M., Minguet, S., Asnafi, V., Lhermitte, L., Mullighan, C. G., Coffelt, S. B., Moriggl, R., Barata, J. T., Pennington, D. J., Silva-Santos, B. (2024) Perinatal thymic-derived CD8αβ-expressing γδ T cells are innate IFN-γ producers that expand in IL-7R-STAT5B-driven neoplasms. Nature Immunology, (doi: 10.1038/s41590-024-01855-4)
Hatthakarnkul, P., Pennel, K., Alexander, P., Van Wyk, H., Roseweir, A., Inthagard, J., Hay, J., Andersen, D., Maka, N., Park, J., Roxburgh, C., Thuwajit, C., McMillan, D., Edwards, J. (2024) Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 10, (doi: 10.1002/2056-4538.12374)
Pennel, K., Dutton, L., Melissourgou-Syka, L., Roxburgh, C., Birch, J., Edwards, J. (2024) Novel radiation and targeted therapy combinations for improving rectal cancer outcomes. Expert Reviews in Molecular Medicine, 26, (doi: 10.1017/erm.2024.15)
Lupo, F., Coffelt, S. B. (2024) Stressed out neutrophils drive metastasis. Immunity, 57, pp. 840-842. (doi: 10.1016/j.immuni.2024.03.013)
Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, (doi: 10.1186/s13046-024-02958-4)
Dawson, A. et al. (2024) Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche. Nature Communications, 15, (doi: 10.1038/s41467-024-45471-0)
Drew, Y. et al. (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30, pp. 50-62. (doi: 10.1158/1078-0432.ccr-23-2249)
2023
Beach, C. et al. (2023) Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1. Journal of Clinical Investigation, 133, (doi: 10.1172/JCI168277)
Neilson, L. J., Cartwright, D., Risteli, M., Jokinen, E. M., McGarry, L., Sandvik, T., Nikolatou, K., Hodge, K., Atkinson, S., Vias, M., Kay, E. J., Brenton, J. D., Carlin, L. M., Bryant, D. M., Salo, T., Zanivan, S. (2023) Omentum-derived matrix enables the study of metastatic ovarian cancer and stromal cell functions in a physiologically relevant environment. Matrix Biology Plus, 19-20, (doi: 10.1016/j.mbplus.2023.100136)
Zarou, M. M., Dawson, A., Prasad, B., Bittencourt-Silvestre, J., Zerbst, D., Rodriguez Blanco, G., Scott, M., Dunn, K., Krishnan, V., Copland, M., Vetrie, D., Bhatia, R., Coffelt, S., Ong, S. T., Wheadon, H., Zanivan, S., Kirschner, K., Helgason, G. V. (2023) Leukaemia Exposure Alters the Transcriptional Profile and Function of Macrophages in the Bone Marrow Niche. (doi: 10.1182/blood-2023-181630)
Greenland, K. K., Pennel, K., Cioccoloni, G., Rogerson, C., Barnieh, F. M., Speirs, V. (2023) Trailblazers in cancer research: the next generation – the British Association of Cancer Research early-career conference. Biology Open, 12, (doi: 10.1242/bio.060121)
Quintana, J. F., Sinton, M. C., Chandrasegaran, P., Lestari, A. N., Heslop, R., Cheaib, B., Ogunsola, J., Ngoyi, D. M., Swar, N.-R. K., Cooper, A., Mabbott, N. A., Coffelt, S. B., MacLeod, A. (2023) γδ T cells control murine skin inflammation and subcutaneous adipose wasting during chronic Trypanosoma brucei infection. Nature Communications, 14, (doi: 10.1038/s41467-023-40962-y)
Suzuki, T. et al. (2023) β-catenin drives butyrophilin-like molecule loss and γδ T-cell exclusion in colon cancer. Cancer Immunology Research, 11, pp. 1137-1155. (doi: 10.1158/2326-6066.CIR-22-0644)
Vande Voorde, J. et al. (2023) Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism, 5, pp. 1303-1318. (doi: 10.1038/s42255-023-00857-0)
Hatthakarnkul, P., Ammar, A., Pennel, K. A.F., Officer-Jones, L., Cusumano, S., Quinn, J. A., Matly, A. A. M., Alexander, P. G., Hay, J., Andersen, D., Lynch, G., Van Wyk, H. C., Maka, N., McMillan, D. C., Le Quesne, J., Thuwajit, C., Edwards, J. (2023) Protein expression of S100A2 reveals it association with patient prognosis and immune infiltration profile in colorectal cancer. Journal of Cancer, 14, pp. 1837-1847. (doi: 10.7150/jca.83910)
Pennel, K., Morrow, E., Hatthakarnkul, P., Leslie, H., Mallon, E., Andersen, D., Jamieson, N., McMillan, D., Roseweir, A., Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12, pp. 13225-13240. (doi: 10.1002/cam4.6014)
Wood, C. S., Pennel, K. A.F., Leslie, H., Legrini, A., Cameron, A. J., Melissourgou-Syka, L., Quinn, J. A., van Wyk, H. C., Hay, J., Roseweir, A. K., Nixon, C., Roxburgh, C. S.D., McMillan, D. C., Biankin, A. V., Sansom, O. J., Horgan, P. G., Edwards, J., Steele, C. W., Jamieson, N. B. (2023) Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases. Cancer Research, 83, pp. 1329-1344. (doi: 10.1158/0008-5472.CAN-22-2794)
Alizzi, Z., Roxburgh, P., Cartwright, D., McLaren, A., Park, S., Jones, R., Greening, S., Hudson, E., Green, C., Gray, S., Khalique, S., Karteris, E., Hall, M. (2023) Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: evaluation of the role of PARP inhibitors in this setting. Journal of Clinical Medicine, 12, (doi: 10.3390/jcm12072497)
Coffelt, S. B., Suzuki, T. (2023) γδ T cells turn the tables on immune-evasive colon cancer. Med, 4, pp. 141-142. (doi: 10.1016/j.medj.2023.02.007)
Alexander, P.G., van Wyk, H.C., Pennel, K.A.F., Hay, J., McMillan, D.C., Horgan, P.G., Roxburgh, C.S.D., Edwards, J., Park, J.H. (2023) The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer. British Journal of Cancer, 128, pp. 556-567. (doi: 10.1038/s41416-022-02069-x)
2022
Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82, pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012)
van Wagensveld, L., van Baal, J. O. A. M., Timmermans, M., Gaillard, D., Borghuis, L., Coffelt, S. B., Rosenberg, E. H., Lok, C. A. R., Nijman, H. W., Kooreman, L. F. S., Sanders, J., de Bruijn, M., Wessels, L. F. A., van der Wiel, R., Rausch, C., Broeks, A., Kruitwagen, R. F. P. M., van der Aa, M. A., Sonke, G. S., Schouten, P. C., Van de Vijver, K. K., Horlings, H. M. (2022) Homologous recombination deficiency and cyclin E1 amplification are correlated with immune cell infiltration and survival in high-grade serous ovarian cancer. Cancers, 14, (doi: 10.3390/cancers14235965)
Pennel, K. A. F., Quinn, J. A., Nixon, C., Inthagard, J., van Wyk, H. C., Chang, D., Rebus, S., GPOL Group, , Hay, J., Maka, N. N., Roxburgh, C. S.D., Horgan, P. G., McMillan, D. C., Park, J. H., Roseweir, A. K., Steele, C. W., Edwards, J. (2022) CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. Journal of Pathology: Clinical Research, 8, pp. 509-520. (doi: 10.1002/cjp2.290)
Edwards, S. C., Hedley, A., Hoevenaar, W. H.M., Wiesheu, R., Glauner, T., Kilbey, A., Shaw, R., Boufea, K., Batada, N., Hatano, S., Yoshikai, Y., Blyth, K., Miller, C., Kirschner, K., Coffelt, S. B. (2022) PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells. Journal of Experimental Medicine, 220, (doi: 10.1084/jem.20211431)
Alexander, P. G., Matly, A. A.M., Jirapongwattana, N., Pennel, K. A.F., Van Wyk, H. C., McMillan, D. C., Horgan, P. G., Roxburgh, C. S.D., Thuwajit, C., Roseweir, A. K., Quinn, J., Park, J. H., Edwards, J. (2022) The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 127, pp. 1-11. (doi: 10.1016/j.humpath.2022.05.012)
Hollis, R. L., Meynert, A. M., Michie, C. O., Rye, T., Churchman, M., Hallas-Potts, A., Croy, I., McCluggage, W. G., Williams, A. R. W., Bartos, C., Iida, Y., Okamoto, A., Dougherty, B., Barrett, J. C., March, R., Matakidou, A., Roxburgh, P., Semple, C. A., Harkin, D. P., Kennedy, R., Herrington, C. S., Gourley, C. (2022) Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification. Clinical Cancer Research, 28, pp. 3546-3556. (doi: 10.1158/1078-0432.CCR-22-0368)
Patel, M., Pennel, K. A.F., Quinn, J. A., Hood, H., Chang, D. K., Biankin, A. V., Rebus, S., Roseweir, A. K., Park, J. H., Horgan, P. G., McMillan, D. C., Edwards, J. (2022) Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer. British Journal of Cancer, 126, pp. 1704-1714. (doi: 10.1038/s41416-022-01729-2)
Lawrence, M., Wiesheu, R., Coffelt, S. B. (2022) The duplexity of unconventional T cells in cancer. International Journal of Biochemistry and Cell Biology, 146, (doi: 10.1016/j.biocel.2022.106213)
Spiliopoulou, P., Spear, S., Mirza, H., Garner, I., Iyer, N., McGarry, L., Grundland-Freile, F., Cheng, Z., Ennis, D. P., McNamara, S., Natoli, M., Mason, S., Blyth, K., Adams, P. D., Roxburgh, P., Fuchter, M. J., Brown, B., McNeish, I. A. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21, pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743)
Wohlmuth, C. et al. (2022) CA-125 levels are predictive of survival in low-grade serous ovarian cancer—a multicenter analysis. Cancers, 14, (doi: 10.3390/cancers14081954)
Paterson, K., Paterson, S., Mulholland, T., Coffelt, S.B., Zagnoni, M. (2022) Assessment of CAR-T mediated and targeted cytotoxicity in 3D microfluidic TBNC co-culture models for combination therapy. IEEE Open Journal of Engineering in Medicine and Biology, 3, pp. 86-95. (doi: 10.1109/OJEMB.2022.3178302)
Curio, S., Edwards, S. C., Suzuki, T., McGovern, J., Triulzi, C., Yoshida, N., Jonsson, G., Glauner, T., Rami, D., Wiesheu, R., Kilbey, A., Purcell, R. V., Coffelt, S. B., Guerra, N. (2022) NKG2D signaling regulates IL-17A-producing γδT cells in mice to promote cancer progression. Discovery Immunology, 1, (doi: 10.1093/discim/kyac002)
2021
Johnson, S. A., Ormsby, M. J., Wessel, H., Hulme, H., Bravo-Blas, A., McIntosh, A., Mason, S., Coffelt, S., Tait, S. W.G., Mcl. Mowat, A., Milling, S., Blyth, K., Wall, D. M. (2021) Monocytes mediate Salmonella Typhimurium-induced tumor growth inhibition in a mouse melanoma model. European Journal of Immunology, 51, pp. 3228-3238. (doi: 10.1002/eji.202048913)
Moreno, V., Barretina-Ginesta, M.-P., García-Donas, J., Jayson, G. C., Roxburgh, P., Vázquez, R. M., Michael, A., Antón-Torres, A., Brown, R., Krige, D., Champion, B., McNeish, I. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9, (doi: 10.1136/jitc-2021-003645)
Spiliopoulou, P., Hinsley, S., Mcneish, I. A., Roxburgh, P., Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467)
Paterson, K., Zanivan, S., Glasspool, R., Coffelt, S.B., Zagnoni, M. (2021) Microfluidic technologies for immunotherapy studies on solid tumours. Lab on a Chip, 21, pp. 2306-2329. (doi: 10.1039/D0LC01305F)
Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27, pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068)
Knight, J. R.P. et al. (2021) MNK inhibition sensitizes KRAS-mutant colorectal cancer to mTORC1 inhibition by reducing eIF4E phosphorylation and c-MYC expression. Cancer Discovery, 11, pp. 1228-1247. (doi: 10.1158/2159-8290.CD-20-0652)
McFarlane, A. J., Fercoq, F., Coffelt, S. B., Carlin, L. M. (2021) Neutrophil dynamics in the tumor microenvironment. Journal of Clinical Investigation, 131, (doi: 10.1172/JCI143759)
Al-Badran, S. S.F., Grant, L., Campo, M. B., Inthagard, J., Pennel, K., Quinn, J., Konanahalli, P., Hayman, L., Horgan, P. G., McMillan, D. C., Roxburgh, C. S.D., Roseweir, A., Park, J. H., Edwards, J. (2021) Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer. Journal of Pathology: Clinical Research, 7, pp. 121-134. (doi: 10.1002/cjp2.193)
Edwards, S. C., Hoevenaar, W. H.M., Coffelt, S. B. (2021) Emerging immunotherapies for metastasis. British Journal of Cancer, 124, pp. 37-48. (doi: 10.1038/s41416-020-01160-5)
2020
Coffelt, S. B., Kabelitz, D., Silva-Santos, B., Kuball, J., Born, W., Bank, I. (2020) Editorial: γδ T Cells in Cancer. Frontiers in Immunology, 11, (doi: 10.3389/fimmu.2020.602411)
Suzuki, T., Hayman, L., Kilbey, A., Edwards, J., Coffelt, S. B. (2020) Gut γδ T cells as guardians, disruptors and instigators of cancer. Immunological Reviews, 298, pp. 198-217. (doi: 10.1111/imr.12916)
Alexander, P.G., Roseweir, A.K., Pennel, K.A.F., van Wyk, H.C., Powell, A.G.M.T., McMillan, D.C., Horgan, P.G., Kelly, C., Hay, J., Sansom, O., Harkin, A., Roxburgh, C.S.D., Graham, J., Church, D.N., Tomlinson, I., Saunders, M., Iveson, T.J., Edwards, J., Park, J.H. (2020) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x)
Millar, R., Kilbey, A., Remak, S.-J., Severson, T. M., Dhayade, S., Sandilands, E., Foster, K., Bryant, D. M., Blyth, K., Coffelt, S. B. (2020) The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer. Molecular Oncology, 14, pp. 1868-1880. (doi: 10.1002/1878-0261.12734)
Dhayade, S., Pietzke, M., Wiesheu, R., Tait-Mulder, J., Athineos, D., Sumpton, D., Coffelt, S., Blyth, K., Vazquez, A. (2020) Impact of formate supplementation on body weight and plasma amino acids. Nutrients, 12, (doi: 10.3390/nu12082181)
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., Neidler, S., Rink, C., Karim, S. A., Gyuraszova, K., Nixon, C., Clark, W., Biankin, A. V., Carlin, L. M., Coffelt, S. B., Sansom, O. J., Morton, J. P., Murphy, D. J. (2020) Repression of the type I interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in pancreatic ductal adenocarcinoma. Cancer Discovery, 10, pp. 872-887. (doi: 10.1158/2159-8290.CD-19-0620)
Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107550)
2019
Wellenstein, M. D., Coffelt, S. B., Duits, D. E.M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., Vrijland, K., Drenth, A. P., de Korte-Grimmerink, R., Schut, E., van der Heijden, I., Zwart, W., Wessels, L. F.A., Schumacher, T. N.M., Jonkers, J., de Visser, K. E. (2019) Loss of p53 triggers Wnt-dependent systemic inflammation to drive breast cancer metastasis. Nature, 572, pp. 538-542. (doi: 10.1038/s41586-019-1450-6)
Mackey, J. B.G., Coffelt, S. B., Carlin, L. M. (2019) Neutrophil maturity in cancer. Frontiers in Immunology, 10, (doi: 10.3389/fimmu.2019.01912)
Tsim, S., Paterson, S., Cartwright, D., Fong, C. J., Alexander, L., Kelly, C., Holme, J., Evison, M., Blyth, K. G. (2019) Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy - Data supporting 'Direct to LAT' in selected groups. Lung Cancer, 133, pp. 123-129. (doi: 10.1016/j.lungcan.2019.05.017)
Silva-Santos, B., Mensurado, S., Coffelt, S. B. (2019) γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nature Reviews Cancer, 19, pp. 392-404. (doi: 10.1038/s41568-019-0153-5)
Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., Song, J.-Y., Ooi, C.-H., Rüttinger, D., Cassier, P. A., Jonkers, J., Schultze, J. L., Ries, C. H., de Visser, K. E. (2019) Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nature Cell Biology, 21, pp. 511-521. (doi: 10.1038/s41556-019-0298-1)
Pennel, K. A.F., Park, J. H., McMillan, D. C., Roseweir, A. K., Edwards, J. (2019) Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: implications for treatment. Cellular Signalling, 54, pp. 81-90. (doi: 10.1016/j.cellsig.2018.11.013)
2018
Kruspig, B., Monteverde, T., Neidler, S., Hock, A., Kerr, E., Nixon, C., Clark, W., Hedley, A., Laing, S., Coffelt, S. B., Le Quesne, J., Dick, C., Vousden, K., Martins, C. P., Murphy, D. J. (2018) The ERBB network facilitates KRAS-driven lung tumorigenesis. Science Translational Medicine, 10, (doi: 10.1126/scitranslmed.aao2565)
2017
Rumney, R. M.H., Coffelt, S. B., Neale, T. A., Dhayade, S., Tozer, G. M., Miller, G. (2017) PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development. PLoS ONE, 12, (doi: 10.1371/journal.pone.0188591)
Walton, J. B., Farquharson, M., Mason, S., Port, J., Kruspig, B., Dowson, S., Stevenson, D., Murphy, D., Matzuk, M., Kim, J., Coffelt, S., Blyth, K., Mcneish, I. A. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, (doi: 10.1038/s41598-017-17119-1)
Carron, E. C., Homra, S., Rosenberg, J., Coffelt, S. B., Kittrell, F., Zhang, Y., Creighton, C. J., Fuqua, S. A., Medina, D., Machado, H. L. (2017) Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget, 8, pp. 50731-50746. (doi: 10.18632/oncotarget.14913)
Wilson, R. H., Evans, T.R. J., Middleton, M. R., Molife, L. R., Spicer, J., Dieras, V., Roxburgh, P., Giordano, H., Jaw-Tsai, S., Goble, S., Plummer, R. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116, (doi: 10.1038/bjc.2017.36)
van Baal, J.O.A.M., Van de Vijver, K.K., Coffelt, S.B., van der Noort, V., van Driel, W.J., Kenter, G.G., Buist, M.R., Lok, C.A.R. (2017) Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study. BJOG: An International Journal of Obstetrics and Gynaecology, 124, pp. 486-494. (doi: 10.1111/1471-0528.14425)
Kersten, K., Coffelt, S. B., Hoogstraat, M., Verstegen, N. J.M., Vrijland, K., Ciampricotti, M., Doornebal, C. W., Hau, C.-S., Wellenstein, M. D., Salvagno, C., Doshi, P., Lips, E. H., Wessels, L. F.A., de Visser, K. E. (2017) Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. OncoImmunology, 6, (doi: 10.1080/2162402X.2017.1334744)
2016
Coffelt, S. B., Wellenstein, M. D., de Visser, K. E. (2016) Neutrophils in cancer: neutral no more. Nature Reviews Cancer, 16, pp. 431-446. (doi: 10.1038/nrc.2016.52)
Coffelt, S. B., de Visser, K. E. (2016) Revving up dendritic cells while braking PD-L1 to jump-start the cancer-immunity cycle motor. Immunity, 44, pp. 722-724. (doi: 10.1016/j.immuni.2016.03.014)
Rahat, M. A., Coffelt, S., Granot, Z., Muthana, M., Amedei, A. (2016) Macrophages and neutrophils: regulation of the inflammatory microenvironment in autoimmunity and cancer. Mediators of Inflammation, 2016, (doi: 10.1155/2016/5894347)
Coffelt, S. B., de Visser, K. E. (2016) Systemic inflammation: Cancer's long-distance reach to maximize metastasis. OncoImmunology, 5, (doi: 10.1080/2162402X.2015.1075694)
• Early-phase ovarian cancer clinical trials.
• Identification of strategies to evade PARP inhibitor (PARPi) resistance in high grade serous ovarian cancer.
• Research into the genomic landscape of ovarian cancer tumour genesis in high risk BRCA 1 / 2 mutation carriers.
• Identification of novel therapies for low grade serous ovarian cancer.
• Spatial analysis of cancer associated with fibroblast subtypes in high grade serous ovarian carcinoma. The date generated will enable researchers to understand which cell types have the most effect on how a tumour grows and how it responds to chemotherapy.